BiondVax Pharmaceuticals ROE 2024

BiondVax Pharmaceuticals Aktienanalyse

What does BiondVax Pharmaceuticals do?

BiondVax Pharmaceuticals Ltd is an Israeli biopharmaceutical company specializing in the development and production of vaccines. The company was founded in 2003 and has since developed an innovative approach to preparing influenza vaccines. BiondVax's business model is focused on meeting the growing demand for vaccines while ensuring better efficacy and safety. The company uses the latest technologies and research methods to carefully examine the properties of viruses and develop tailor-made vaccines based on that information. BiondVax offers a wide range of products that focus on protecting against influenza viruses. The company's most important product is the M-001 vaccine, which has broad efficacy against various types of influenza viruses. This vaccine differs from conventional vaccines by independently stimulating and enhancing immunity, resulting in longer-lasting protection. The company is also developing other vaccines aimed at protecting against other infectious diseases such as herpes simplex or AIDS. A unique feature of BiondVax is the use of a targeted approach to cancer treatment, where the patient's immune system is specifically activated to kill cancer cells. BiondVax is a dynamic company that continuously invests in improving its technology and products. Since its founding, the company has made significant progress and achieved a number of milestones. For example, in 2017, the company received an important approval from the US Food and Drug Administration, allowing it to conduct a clinical trial process for its vaccine. BiondVax has also formed partnerships with other leading companies in the healthcare industry to support its research and development. Collaborating with companies such as Merck, Novartis, or the US Department of Defense allows BiondVax to further expand its business and develop more effective vaccines. Over the years, BiondVax has introduced numerous innovations in the industry. For example, the company has specialized in designing peptides, which are proteins that can serve as the basis for vaccines. The company has also utilized the latest technologies in immunology to make its vaccines even safer and more effective. Overall, BiondVax Pharmaceuticals Ltd has made impressive progress in recent years and has established itself as a leading company in the field of vaccine development. Through its innovative technologies and targeted approach to disease prevention, BiondVax is able to significantly impact the healthcare industry and serve a wider range of patients than before. BiondVax Pharmaceuticals ist eines der beliebtesten Unternehmen auf Eulerpool.com.

ROE Details

Decoding BiondVax Pharmaceuticals's Return on Equity (ROE)

BiondVax Pharmaceuticals's Return on Equity (ROE) is a fundamental metric evaluating the company's profitability relative to its equity. Calculated by dividing net income by shareholder's equity, ROE illustrates how effectively the company is generating profits from shareholders’ investments. A higher ROE represents enhanced efficiency and profitability.

Year-to-Year Comparison

Analyzing BiondVax Pharmaceuticals's ROE on a yearly basis aids in tracking its profitability trends and financial performance. An increasing ROE suggests enhanced profitability and value generation for shareholders, whereas a declining ROE may indicate issues in profit generation or equity management.

Impact on Investments

BiondVax Pharmaceuticals's ROE is instrumental for investors assessing the company's profitability, efficiency, and investment attractiveness. A robust ROE indicates the firm’s adeptness at converting equity investments into profits, thereby enhancing its appeal to potential and current investors.

Interpreting ROE Fluctuations

Changes in BiondVax Pharmaceuticals’s ROE can emanate from variations in net income, equity capital, or both. These fluctuations are scrutinized to evaluate management’s effectiveness, financial strategies, and the inherent risks and opportunities, aiding investors in making informed decisions.

Frequently Asked Questions about BiondVax Pharmaceuticals Stock

What is the ROE (Return on Equity) of BiondVax Pharmaceuticals this year?

The ROE of BiondVax Pharmaceuticals this year is -1.79 undefined.

How has the Return on Equity (ROE) of BiondVax Pharmaceuticals developed compared to the previous year?

The ROE of BiondVax Pharmaceuticals has increased by 0% decreased compared to the previous year.

What impact does a high ROE (Return on Equity) have on investors of BiondVax Pharmaceuticals?

A high ROE indicates that BiondVax Pharmaceuticals generates good returns on capital and is successful in monetizing its investments. This is a positive indicator for investors.

What impact does a low ROE (Return on Equity) have on investors of BiondVax Pharmaceuticals?

A low ROE can indicate that BiondVax Pharmaceuticals is having difficulties monetizing its investments successfully and can be a negative signal for investors.

How does a change in the ROE (Return on Equity) of BiondVax Pharmaceuticals affect the company?

A change in ROE (Return on Equity) of BiondVax Pharmaceuticals can be an indicator of the financial performance of the company and demonstrate how successful the company is compared to other companies in the same industry.

How to calculate the ROE (Return on Equity) of BiondVax Pharmaceuticals?

The ROE (Return on Equity) is calculated by dividing the company's profit by the total equity. The formula is: ROE = Profit / Total equity.

Which factors influence the ROE (Return on Equity) of BiondVax Pharmaceuticals?

Some factors that can influence BiondVax Pharmaceuticals's Return on Equity (ROE) include the efficiency in using equity, the profitability of the company, and the financing structure.

What strategic measures can take to improve the ROE (Return on Equity)?

To improve the Return on Equity (ROE), can take measures such as cost savings, increasing revenue, improving efficiency in the use of equity, and making changes in the financing structure. It is important for the company to conduct a thorough review of its financial situation to determine the best strategic actions to improve ROE.

How much dividend does BiondVax Pharmaceuticals pay?

Over the past 12 months, BiondVax Pharmaceuticals paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, BiondVax Pharmaceuticals is expected to pay a dividend of 0 ILS.

What is the dividend yield of BiondVax Pharmaceuticals?

The current dividend yield of BiondVax Pharmaceuticals is .

When does BiondVax Pharmaceuticals pay dividends?

BiondVax Pharmaceuticals pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of BiondVax Pharmaceuticals?

BiondVax Pharmaceuticals paid dividends every year for the past 0 years.

What is the dividend of BiondVax Pharmaceuticals?

For the upcoming 12 months, dividends amounting to 0 ILS are expected. This corresponds to a dividend yield of 0 %.

In which sector is BiondVax Pharmaceuticals located?

BiondVax Pharmaceuticals is assigned to the 'Health' sector.

Wann musste ich die Aktien von BiondVax Pharmaceuticals kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of BiondVax Pharmaceuticals from 7/2/2024 amounting to 0 ILS, you needed to have the stock in your portfolio before the ex-date on 7/2/2024.

When did BiondVax Pharmaceuticals pay the last dividend?

The last dividend was paid out on 7/2/2024.

What was the dividend of BiondVax Pharmaceuticals in the year 2023?

In the year 2023, BiondVax Pharmaceuticals distributed 0 ILS as dividends.

In which currency does BiondVax Pharmaceuticals pay out the dividend?

The dividends of BiondVax Pharmaceuticals are distributed in ILS.